FDA issues complete response letter for Summit's ivonescimab in EGFR-mutant NSCLC
The agency found HARMONi's progression-free survival gain, without a significant overall survival improvement, did not show substantial evidence of effectiveness or a positive benefit-risk profile.
Summit Therapeutics said on 15 November 2026 that the US Food and Drug Administration has issued a Complete Response Letter for its Biologics License Application for ivonescimab. The product was proposed in combination with platinum chemotherapy for locally advanced or metastatic non-small cell lung cancer after prior treatment with an EGFR tyrosine kinase inhibitor.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Summit Therapeutics Inc. ↗
Article written by VigiEye from the official source (Summit Therapeutics Inc.). Claims are the company's own. AI-assisted; check the source before acting.